Quarterly report · Q3
4543.TEDINET S100Q6KM
Period2022-04-01 → 2022-12-31
Filed2023-02-13
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥618.0bn | 2022-04-01 → 2022-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥214.7bn | 2022-10-01 → 2022-12-31d | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥523.5bn | 2021-04-01 → 2021-12-31 | Cons. | Revenue IFRS |
| Revenue | ¥178.8bn | 2021-10-01 → 2021-12-31d | Cons. | Revenue IFRS |
| Operating income | ¥93.5bn | 2022-04-01 → 2022-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Operating profit loss IFRS |
| Operating income | ¥94.5bn | 2021-04-01 → 2021-12-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥28.6bn | 2021-10-01 → 2021-12-31d | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥92.1bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥37.5bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥93.0bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥27.8bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥71.7bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥21.7bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥70.2bn | 2022-04-01 → 2022-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥29.9bn | 2022-10-01 → 2022-12-31d | Cons. | Profit loss IFRS |
| Net income | ¥71.7bn | 2021-04-01 → 2021-12-31 | Cons. | Profit loss IFRS |
| Net income | ¥21.7bn | 2021-10-01 → 2021-12-31d | Cons. | Profit loss IFRS |
| Total assets | ¥1.54T | at 2022-12-31 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.40T | at 2021-12-31 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥469.8bn | at 2022-12-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.07T | at 2022-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥935.9bn | at 2021-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.07T | at 2022-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥935.9bn | at 2021-12-31 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥162.4bn | at 2022-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥204.9bn | at 2021-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥74.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥98.4bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥41.9bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥59.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥84.5bn | 2022-04-01 → 2022-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥39.3bn | 2021-04-01 → 2021-12-31 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥93.25 | 2022-04-01 → 2022-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥39.97 | 2022-10-01 → 2022-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥94.82 | 2021-04-01 → 2021-12-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥28.7 | 2021-10-01 → 2021-12-31d | Cons. | Basic earnings loss per share IFRS |
| EPS (diluted) | ¥93.21 | 2022-04-01 → 2022-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥39.96 | 2022-10-01 → 2022-12-31d | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥94.76 | 2021-04-01 → 2021-12-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥28.69 | 2021-10-01 → 2021-12-31d | Cons. | Diluted earnings loss per share IFRS |
| Equity ratio | 69.6% | at 2022-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 66.8% | at 2021-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 20
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2022-12-31 | ¥186m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-12-31 | ¥479m |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥113.4bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥358.9bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥83.6bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2022-12-31 | ¥145.5bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2022-12-31 | ¥12.6bn |
| —segment total | revenue external | 2022-04-01 → 2022-12-31 | ¥617.8bn |
| —segment total | segment profit | 2022-04-01 → 2022-12-31 | ¥109.1bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2021-12-31 | ¥190m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-12-31 | −¥1.7bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥90.2bn |
| jpcrp040300-q3r_E01630-000Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥17.2bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥294.4bn |
| jpcrp040300-q3r_E01630-000Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥72.3bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2021-12-31 | ¥138.7bn |
| jpcrp040300-q3r_E01630-000Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2021-12-31 | ¥19.3bn |
| —segment total | revenue external | 2021-04-01 → 2021-12-31 | ¥523.3bn |
| —segment total | segment profit | 2021-04-01 → 2021-12-31 | ¥108.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 648
| Item | Context | Value | Unit |
|---|---|---|---|
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 4291000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | 8626000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | Prior1YTDDuration | 4135000000 | JPY |
| Net increase decrease in cash and cash equivalents IFRS | CurrentYTDDuration | -42863000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 200770000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 204905000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 162388000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 294403000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 138733000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 90154000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 523291000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | 190000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 523482000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 72326000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 19345000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 17191000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 108862000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -1705000000 | JPY |
| Segment profit loss IFRS | Prior1YTDDuration | 107157000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -5496000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -6294000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReportableSegmentsMember | -11791000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration_ReconcilingItemsMember | -50000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YTDDuration | -11841000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YTDDuration | -860000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 94455000000 | JPY |
| Finance income IFRS | Prior1YTDDuration | 759000000 | JPY |
| Finance costs IFRS | Prior1YTDDuration | 2603000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YTDDuration | 433000000 | JPY |
| Profit loss before tax IFRS | Prior1YTDDuration | 93044000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 358907000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 145511000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 113388000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 617807000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | 186000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 617993000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 83598000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 12605000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 12924000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReportableSegmentsMember | 109127000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration_ReconcilingItemsMember | 479000000 | JPY |
| Segment profit loss IFRS | CurrentYTDDuration | 109607000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -6770000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_jpcrp040300-q3r_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -7633000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReportableSegmentsMember | -14403000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration_ReconcilingItemsMember | 4000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | CurrentYTDDuration | -14399000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 16 of 16 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |